Investigating how therapeutic vaccines can help control HIV-1 infection
Official title: Multi-Omics Correlates of Therapeutic Vaccine Efficacy
Funded at Beth Israel Deaconess Medical Center · NIH-11084521 · Data updated 2026-11-12
This study is looking at ways to boost the immune system's ability to fight HIV-1, aiming to help people control the virus without needing daily medication, and it will use monkeys to learn more about how different vaccines can improve immune responses.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 11, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $251,823 |
| NIH project number | 5P01AI177687-03 |
| Project ID | NIH-11084521 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are interested in innovative treatment options and have not achieved viral suppression with standard ART.
✕Less likely to help
Patients who are not infected with HIV or those who have advanced AIDS with significant immune compromise may not benefit from this research.
What this research studies
This research aims to enhance the immune response against HIV-1 through therapeutic vaccination, striving for a functional cure that allows patients to maintain viral control without antiretroviral therapy (ART). The study will analyze immune responses in SIV/SHIV-infected rhesus macaques to identify immune signatures associated with successful viral control. By employing advanced multi-omics techniques, researchers will explore how different immunization strategies affect immune responses in lymphoid tissues, which are critical for managing the virus. The findings could lead to improved vaccine designs for humans.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic vaccines that help patients achieve long-term control of HIV-1 without the need for continuous medication.
How similar studies have gone: Previous studies in non-human primates have shown promising results with therapeutic vaccines, indicating potential for success in human applications.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Juelg, Boris Dominik — Beth Israel Deaconess Medical Center
- Study coordinator: Juelg, Boris Dominik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.